Mölnlycke acquires German wound care company SastoMed GmbH
The world-leading medical solutions company, Mölnlycke, has acquired German wound care products company, SastoMed GmbH. The deal adds new, award-winning products to Mölnlycke’s offer – enabling it to further help healthcare professionals and patients by accelerating the wound healing process and treating chronic wounds.
As of 2 July, SastoMed GmbH joins the Mölnlycke family, bringing two innovative and complementary products to Mölnlycke’s wound care portfolio:
- Granulox®: a haemoglobin-based topical oxygen therapy spray that is sprayed on wounds for faster wound healing
- Granudacyn®: a hypochlorous wound irrigation solution for cleaning, moistening and rinsing of acute, chronic and contaminated wounds, and first and second degree burns
The addition of the new products will enable Mölnlycke to lead the way in both active and passive wound healing.
‘Today, chronic wounds, such as foot ulcers, have a higher mortality rate than both breast cancer and prostate cancer and the real burden of ulcers is not yet fully known or understood. Mölnlycke will now be able to offer healthcare professionals – and patients – solutions to support both active and passive healing. We can therefore offer a holistic approach to wound treatment through our portfolio’, says Mölnlycke CEO, Richard Twomey.
With the acquisition of SastoMed GmbH, Mölnlycke adds another award-winning product to its wound care offer. Earlier this year, Granulox won the 2018 Innovation Award at EWMA (European Wound Management Association)
Complementary innovation and sales capabilities
Over the past few years, Mölnlycke has invested in organic R&D to meet customer needs and bring innovative products to the market. The acquisition complements this investment with new technology and capabilities, further accelerating Mölnlycke’s potential for product innovation.
Furthermore, both Granulox and Granudacyn fit into Mölnlycke’s strategy to be a category leader within the wound care space.
Share the desire to help patients
While Granulox is currently available in more than 24 countries, SastoMed’s main customer base is in Germany, South East Asia and Central and Latin America. Mölnlycke will expand the geographical reach of Granulox and Granudacyn through its worldwide distribution network and sales organisation. With customers and a salesforce in South East Asia and Central and Latin America, the acquisition of SastoMed also enables Mölnlycke to expand its presence in key growth markets.
The founder of SastoMed, Michael Sander, comments: ‘We share Mölnlycke’s desire to advance healthcare around the world. Too often, patients experience slow wound healing since no appropriate therapy is available to overcome the lack of oxygen in the wound tissue. Now we feel it´s the right time to pass the baton to the leading company in advanced wound care, in order to make our unique products available to as many patients as possible.’
For more information, please contact:
Jenny Johansson, Global Communications Manager, Corporate Communications
firstname.lastname@example.org, +46 739 41 29 23
Mölnlycke is a world leading medical solutions company. We develop and bring to market innovative wound care and surgical solutions along the entire continuum of care – from prevention to post-acute settings. Our solutions provide value for money, supported by clinical and health economic evidence.
Mölnlycke was founded in 1849. Nowadays, our solutions are available in around 100 countries; we are the number one global provider of advanced wound care and single-use surgical products; and we are Europe’s largest provider of customized trays. Our headquarters are in Gothenburg, Sweden and we have about 7,700 employees around the world. Learn more at molnlycke.com.
About SastoMed GmbH
SastoMed is a German Biotech company, belonging to the SanderStrothmann Group of companies. The enterprises focus on developing innovative products in the field of medical device, cosmetics and biocidal products. SastoMed was founded in 2010 to develop, register and commercialise an oxygen based wound treatment.